CKM Syndrome and the Importance of Early Detection and Intervention
Viet Le, DMSc, MPAS, PA-C, FACC, FAHA, HF-Cert
In this four-part educational series, PA Viet Le provides a practical, stage-by-stage guide to identifying and managing Cardio-Kidney-Metabolic (CKM) syndrome. He covers the root causes and clinical staging, the biomarkers and screening tools that reveal organ involvement before symptoms appear, and two real-world patient cases that illustrate how CKM can progress when intervention is delayed.
Grounded in 2026 clinical practice guidelines, the series gives PAs concrete strategies for earlier risk identification, accurate staging and documentation, and timely, guideline-directed treatment.
Video 1: CKM Screening and Staging
Explore the root causes of CKM syndrome and learn how to apply the latest staging framework and screening recommendations in daily practice.
Video 2: CKM Screening Can’t Wait: Using Biomarkers to Detect Progression
Discover how key biomarkers like eGFR, UACR, and NT-proBNP can reveal kidney and cardiovascular risk before symptoms appear.
Video 3: Identifying Stage 1 CKM in a Patient Case
Follow a real-world patient case to see how obesity, staging, and risk calculators come together to guide early CKM intervention.
Video 4: CKM Progression in the Absence of Intervention
Revisit the patient case from the previous video two years later to see how unaddressed CKM risk factors progress and learn strategies for swift, guideline-directed treatment.
Supported by
